Charcot Neuroarthropathy in Diabetic Patients

Charcot neuroarthropathy (CN) in diabetic patients is a destructive complication of peripheral neuropathy characterised by progressive bone and joint disintegration in the foot and ankle. Although relatively uncommon, its global incidence is rising in line with the diabetes pandemic. The condition arises chiefly from sensory neuropathy, which impairs detection of microtrauma and precipitates inflammatory bone resorption. Consequent joint instability and structural collapse may rapidly lead to severe deformity, ulceration, infection and limb amputation. Early-stage diagnoses are challenging, as plain radiography may remain normal despite active disease, making magnetic resonance imaging indispensable. Management focuses on immobilisation and off-loading in the acute phase to halt osteolysis, followed by customised orthoses or surgical reconstruction to restore foot architecture. Advances in understanding the molecular drivers—particularly inflammatory mediators and bone remodelling pathways—have opened avenues for pharmacological intervention. Despite consensus on early detection and multidisciplinary care, long-term outcomes hinge on patient education, glycaemic control and prompt referral. Continued research seeks to refine risk stratification, enhance diagnostic precision and develop targeted therapies to preserve limb function and quality of life worldwide.

Research from Nature Portfolio

A genetic analysis of the OPG–RANKL–RANK axis has revealed distinctive single-nucleotide polymorphism profiles in patients with Charcot arthropathy compared with diabetic or neuropathic controls. Two co-occurring OPG polymorphisms emerged as potential molecular markers for early detection, while hierarchical clustering of multiple variants delineated a specific genotype signature associated with disease onset. These findings suggest that genotyping may inform risk stratification and uncover mechanistic insights into dysregulated bone metabolism, laying the groundwork for precision medicine approaches in Charcot neuroarthropathy.

Charcot Neuroarthropathy in Diabetic Patients publication trend

The graph below shows the total number of articles in charcot neuroarthropathy in diabetic patients across all publications each year (not limited to Nature Index journals).

Technical terms

Charcot neuroarthropathy (Charcot foot): A degenerative joint condition in the foot caused by neuropathy, leading to bone and joint destruction.

Peripheral neuropathy: Nerve damage in the limbs that results in impaired sensation and increases risk of unnoticed injury.

Receptor activator of nuclear factor-κB ligand (RANKL): A molecule that stimulates osteoclast formation and bone resorption.

Osteoprotegerin (OPG): A decoy receptor that binds RANKL, inhibiting bone resorption.

Off-loading: The redistribution or removal of weight from the affected foot to avoid further mechanical stress.

References

1. Risk factors for Charcot foot development in individuals with diabetes mellitus. Diabetologia (2024).
2. Guidelines on the diagnosis and treatment of active Charcot neuro‐osteoarthropathy in persons with diabetes mellitus (IWGDF 2023). Diabetes/Metabolism Research and Reviews (2023).
3. RANKL-RANK-OPG Pathway in Charcot Diabetic Foot: Pathophysiology and Clinical-Therapeutic Implications. International Journal of Molecular Sciences (2023).
4. The acute diabetic Charcot foot managed on the basis of magnetic resonance imaging – a review of 71 cases. Swiss Medical Weekly (2013).
5. Prevalence of polymorphisms in OPG, RANKL and RANK as potential markers for Charcot arthropathy development. Scientific Reports (2017).